NASDAQ:BYSIBeyondspring Stock Price, Forecast & News

$17.00

-0.02 (-0.12 %)

(As of 05/28/2020 11:17 AM ET)

Add

Compare

Today's Range

$16.98

Now: $17.00▼

$17.75

50-Day Range

$11.95

MA: $14.65▼

$18.15

52-Week Range

$9.38

Now: $17.00▼

$24.80

Volume714 shs

Average Volume48,405 shs

Market Capitalization$474.13 million

P/E RatioN/A

Dividend YieldN/A

Beta1.11

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab. BeyondSpring Inc. was founded in 2010 and is headquartered in New York, New York.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Beyondspring has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $29.67, Beyondspring has a potential upside of 74.5% from its current price of $17.00.
Amount of Analyst Coverage
Beyondspring has only been the subject of 2 research reports in the past 90 days.

2.6 Community Rank

Outperform Votes
Beyondspring has received 163 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Beyondspring has received 150 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Beyondspring has received 52.08% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Beyondspring and other stocks. Vote “Outperform” if you believe BYSI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BYSI will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Beyondspring does not currently pay a dividend.
Dividend Growth
Beyondspring does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Beyondspring insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 6.60% of the stock of Beyondspring is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Beyondspring are expected to grow in the coming year, from ($1.98) to ($1.89) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Beyondspring is -11.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Beyondspring is -11.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Beyondspring has a P/B Ratio of 15.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.35 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:BYSI

Previous Symbol

CUSIPN/A

CIK1677940

Webwww.beyondspringpharma.com

Phone1-646-305-6387

Debt

Debt-to-Equity Ratio0.11

Current Ratio4.06

Quick Ratio4.06

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.12 per share

Price / Book15.18

Profitability

EPS (Most Recent Fiscal Year)($1.55)

Net Income$-38,080,000.00

Net MarginsN/A

Return on Equity-431.19%

Return on Assets-171.68%

Miscellaneous

EmployeesN/A

Outstanding Shares27,890,000

Market Cap$474.13 million

Next Earnings Date7/8/2020 (Estimated)

OptionableNot Optionable

Receive BYSI News and Ratings via Email

Sign-up to receive the latest news and ratings for BYSI and its competitors with MarketBeat's FREE daily newsletter.

Beyondspring (NASDAQ:BYSI) Frequently Asked Questions

How has Beyondspring's stock been impacted by COVID-19 (Coronavirus)?

Beyondspring's stock was trading at $11.35 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BYSI shares have increased by 49.8% and is now trading at $17.00. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Beyondspring?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beyondspring in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Beyondspring.

When is Beyondspring's next earnings date?

Beyondspring is scheduled to release its next quarterly earnings announcement on Wednesday, July 8th 2020. View our earnings forecast for Beyondspring.

How were Beyondspring's earnings last quarter?

Beyondspring Inc (NASDAQ:BYSI) posted its quarterly earnings data on Thursday, April, 30th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.43) by $0.09. View Beyondspring's earnings history.

What price target have analysts set for BYSI?

4 brokerages have issued 1 year price objectives for Beyondspring's stock. Their forecasts range from $25.00 to $34.00. On average, they expect Beyondspring's stock price to reach $29.67 in the next year. This suggests a possible upside of 74.5% from the stock's current price. View analysts' price targets for Beyondspring.

Has Beyondspring been receiving favorable news coverage?

Press coverage about BYSI stock has been trending somewhat negative on Thursday, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Beyondspring earned a news impact score of -1.7 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutBeyondspring.

Who are some of Beyondspring's key competitors?

Some companies that are related to Beyondspring include Xencor (XNCR), Eidos Therapeutics (EIDX), Aurinia Pharmaceuticals (AUPH), Zymeworks (ZYME), Arvinas (ARVN), Corcept Therapeutics (CORT), Heron Therapeutics (HRTX), Ligand Pharmaceuticals (LGND), Theravance Biopharma (TBPH), Ironwood Pharmaceuticals (IRWD), Zogenix (ZGNX), INDIVIOR PLC/S (INVVY), Akebia Therapeutics (AKBA), Y-mAbs Therapeutics (YMAB) and Opko Health (OPK). View all competitors.

What other stocks do shareholders of Beyondspring own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Beyondspring investors own include Exelixis (EXEL), Enterprise Products Partners (EPD), Intel (INTC), AbbVie (ABBV), Gilead Sciences (GILD), Johnson & Johnson (JNJ), JPMorgan Chase & Co. (JPM), Verizon Communications (VZ), Crispr Therapeutics (CRSP) and Enbridge (ENB).

Who are Beyondspring's key executives?

Beyondspring's management team includes the following people:

Dr. Lan Huang, Co-Founder, Chairman & CEO (Age 48)
Mr. Dongheng Liu, Chief Financial Officer (Age 37)
Mr. Richard J. Daly M.B.A., Chief Operating Officer (Age 58)
Dr. Ramon W. Mohanlal, Exec. VP of R&D and Chief Medical Officer (Age 61)
Dr. G. Kenneth Lloyd, Chief Scientific Officer (Age 75)

When did Beyondspring IPO?

(BYSI) raised $4 million in an initial public offering on Thursday, March 9th 2017. The company issued 200,000 shares at $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) acted as the underwriter for the IPO.

What is Beyondspring's stock symbol?

Beyondspring trades on the NASDAQ under the ticker symbol "BYSI."

Who are Beyondspring's major shareholders?

Beyondspring's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.65%), State Street Corp (0.74%), Fosun International Ltd (0.56%), Geode Capital Management LLC (0.34%), Russell Investments Group Ltd. (0.13%) and Wells Fargo & Company MN (0.11%).

Which major investors are selling Beyondspring stock?

BYSI stock was sold by a variety of institutional investors in the last quarter, including Fosun International Ltd, Morgan Stanley, UBS Group AG, Deutsche Bank AG, and Federated Hermes Inc..

Which major investors are buying Beyondspring stock?

BYSI stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., BlackRock Inc., Geode Capital Management LLC, Alliancebernstein L.P., Rhumbline Advisers, State Street Corp, Wells Fargo & Company MN, and BNP Paribas Arbitrage SA.

How do I buy shares of Beyondspring?

Shares of BYSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Beyondspring's stock price today?

One share of BYSI stock can currently be purchased for approximately $17.00.

How big of a company is Beyondspring?

Beyondspring has a market capitalization of $474.13 million. The company earns $-38,080,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis.

What is Beyondspring's official website?

The official website for Beyondspring is www.beyondspringpharma.com.

How can I contact Beyondspring?

Beyondspring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The company can be reached via phone at 1-646-305-6387 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff